肿瘤防治研究2026，Vol.53Issue(4)：281-288,8.DOI:10.3971/j.issn.1000-8578.2026.25.0749
CAR-NK疗法在急性髓系白血病中的应用研究进展
Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia
摘要
Abstract
Chimeric antigen receptor(CAR)T-cell therapy for B-cell hematologic malignancies has achieved breakthrough success;however,its efficacy for acute myeloid leukemia(AML)is constrained by the lack of highly specific tumor antigens and the expression of shared targets on normal hematopoietic stem/progenitor cells,increasing the risk of on-target myelosuppression and cytokine release syndrome(CRS).By contrast,CAR-NK cell therapy,an emerging strategy that leverages the innate antitumor activity of natural killer cells,is associated with low rates of CRS and graft-versus-host disease.Early clinical studies also indicate its favorable safety profile with preliminary antileukemic activity.This review summarizes recent advances in CAR-NK therapy for AML and discusses future directions and potential avenues for clinical translation.关键词
急性髓系白血病/自然杀伤细胞/免疫治疗/CAR-NKKey words
Acute myeloid leukemia/Natural killer cell/Immunotherapy/CAR-NK分类
医药卫生引用本文复制引用
苏帅,肖毅..CAR-NK疗法在急性髓系白血病中的应用研究进展[J].肿瘤防治研究,2026,53(4):281-288,8.基金项目
National Natural Science Foundation of China(Nos.81873444,82070213,82370196) 国家自然科学基金(81873444,82070213,82370196) （Nos.81873444,82070213,82370196）
